Roles of the Functional Interaction between Brain Cholinergic and Dopaminergic Systems in the Pathogenesis and Treatment of Schizophrenia and Parkinson's Disease

被引:22
作者
Acharya, Srijan [1 ,2 ,3 ]
Kim, Kyeong-Man [1 ]
机构
[1] Chonnam Natl Univ, Coll Pharm, Pharmacol Lab, Gwang Ju 61186, South Korea
[2] Univ S Alabama, Dept Pathol, Coll Med, Mobile, AL 36617 USA
[3] Univ S Alabama, Mitchell Canc Inst, Canc Biol Program, Mobile, AL 36604 USA
基金
新加坡国家研究基金会;
关键词
dopamine; nicotine; receptor; schizophrenia; Parkinson’ s disease; L-DOPA; NICOTINIC ACETYLCHOLINE-RECEPTORS; VENTRAL TEGMENTAL AREA; DOPA-INDUCED DYSKINESIA; LEVODOPA-INDUCED DYSKINESIAS; MESSENGER-RNA EXPRESSION; DENDRITIC SPINE DENSITY; MEDIATED NEUROPROTECTION; PREFRONTAL CORTEX; SUBSTANTIA-NIGRA; GLUTAMATERGIC DYSFUNCTION;
D O I
10.3390/ijms22094299
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Most physiologic processes in the brain and related diseases involve more than one neurotransmitter system. Thus, elucidation of the interaction between different neurotransmitter systems could allow for better therapeutic approaches to the treatments of related diseases. Dopaminergic (DAergic) and cholinergic neurotransmitter system regulate various brain functions that include cognition, movement, emotion, etc. This review focuses on the interaction between the brain DAergic and cholinergic systems with respect to the pathogenesis and treatment of schizophrenia and Parkinson's disease (PD). We first discussed the selection of motor plans at the level of basal ganglia, the major DAergic and cholinergic pathways in the brain, and the receptor subtypes involved in the interaction between the two signaling systems. Next, the roles of each signaling system were discussed in the context of the negative symptoms of schizophrenia, with a focus on the alpha 7 nicotinic cholinergic receptor and the dopamine D-1 receptor in the prefrontal cortex. In addition, the roles of the nicotinic and dopamine receptors were discussed in the context of regulation of striatal cholinergic interneurons, which play crucial roles in the degeneration of nigrostriatal DAergic neurons and the development of L-DOPA-induced dyskinesia in PD patients. Finally, we discussed the general mechanisms of nicotine-induced protection of DAergic neurons.
引用
收藏
页数:23
相关论文
共 207 条
  • [1] Do we still believe in the dopamine hypothesis? New data bring new evidence
    Abi-Dargham, A
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S1 - S5
  • [2] Metabotropic signaling cascade involved in α4β2 nicotinic acetylcholine receptor-mediated PKCβII activation
    Acharya, Srijan
    Kundu, Dooti
    Choi, Hyun Jin
    Kim, Kyeong-Man
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2020, 1867 (08):
  • [3] α4β2 nicotinic acetylcholine receptor downregulates D3 dopamine receptor expression through protein kinase C activation
    Acharya, Srijan
    Kim, Kyeong-Man
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2019, 514 (03) : 665 - 671
  • [4] Role of dopamine D1 receptors in the control of striatal acetylcholine release by endogenous dopamine
    Acquas, E
    Di Chiara, G
    [J]. NEUROLOGICAL SCIENCES, 2001, 22 (01) : 41 - 42
  • [5] Role of glutamatergic system and mesocorticolimbic circuits in alcohol dependence
    Alasmari, Fawaz
    Goodwani, Sunil
    McCullumsmith, Robert E.
    Sari, Youssef
    [J]. PROGRESS IN NEUROBIOLOGY, 2018, 171 : 32 - 49
  • [6] THE FUNCTIONAL-ANATOMY OF BASAL GANGLIA DISORDERS
    ALBIN, RL
    YOUNG, AB
    PENNEY, JB
    [J]. TRENDS IN NEUROSCIENCES, 1989, 12 (10) : 366 - 375
  • [7] Smoking and Parkinson's disease: Systematic review of prospective studies
    Allam, MF
    Campbell, MJ
    Hofman, A
    Del Castillo, AS
    Navajas, RFC
    [J]. MOVEMENT DISORDERS, 2004, 19 (06) : 614 - 621
  • [8] The relationship between brain structure and neurocognition in schizophrenia: a selective review
    Antonova, E
    Sharma, T
    Morris, R
    Kumari, V
    [J]. SCHIZOPHRENIA RESEARCH, 2004, 70 (2-3) : 117 - 145
  • [9] Novel Dopamine Therapeutics for Cognitive Deficits in Schizophrenia
    Arnsten, Amy F. T.
    Girgis, Ragy R.
    Gray, David L.
    Mailman, Richard B.
    [J]. BIOLOGICAL PSYCHIATRY, 2017, 81 (01) : 67 - 77
  • [10] Dopamine's Actions in Primate Prefrontal Cortex: Challenges for Treating Cognitive Disorders
    Arnsten, Amy F. T.
    Wang, Min
    Paspalas, Constantinos D.
    [J]. PHARMACOLOGICAL REVIEWS, 2015, 67 (03) : 681 - 696